BTMD biote Corp.
Medicinal Chemicals & Botanical Products · Nasdaq · SEC CIK 1819253 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-8.6%
TTM net income YoY-106.7%
TTM EPS YoY-108.9%
Revenue 3-yr CAGR-1.0%
Net income 3-yr CAGR—
Margins
Gross margin67.5%
Operating margin5.0%
Net margin-1.1%
FCF margin4.1%
EBITDA margin6.6%
Returns
ROE—
ROA-1.8%
ROIC (approx.)18.5%
Asset turnover1.68x
Leverage & solvency
Liabilities / assets156.6%
Debt / equity—
Current ratio1.37x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-7.26x
Accruals ratio-14.9%
Payout ratio—
Capex / revenue3.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $192.22M | $197.19M | $185.36M | $164.96M | $139.40M |
| Cost of revenue | $54.86M | $58.13M | $57.88M | $54.58M | $48.82M |
| Gross profit | $137.36M | $139.06M | $127.48M | $110.38M | $90.58M |
| SG&A expense | $101.81M | $107.45M | $98.83M | $171.10M | $49.05M |
| Operating income | $35.55M | $31.61M | $28.66M | -$60.72M | $34.56M |
| Pretax income | $37.58M | $1.02M | -$123,000 | $1.71M | $32.91M |
| Income tax | $5.99M | $970,000 | $2.68M | $388,000 | $286,000 |
| Net income | $27.05M | $3.16M | $3.32M | -$969,000 | $11.11M |
| EBITDA | $39.22M | $35.19M | $31.65M | -$58.52M | $35.96M |
| EPS (basic) | 0.86 | 0.09 | 0.13 | -0.12 | — |
| EPS (diluted) | 0.74 | 0.09 | 0.13 | -0.12 | — |
| Weighted avg. shares (diluted) | 36.67M | 34.27M | 25.71M | 8.06M | — |
| Balance sheet | |||||
| Cash & equivalents | $24.12M | $39.34M | $89.00M | $79.23M | $26.77M |
| Receivables | $6.87M | $7.63M | $6.81M | $6.95M | $5.23M |
| Inventory | $19.06M | $14.85M | $17.31M | $11.18M | $9.62M |
| Current assets | $54.67M | $68.13M | $122.34M | $101.18M | $47.09M |
| PP&E, net | $10.75M | $6.97M | $1.22M | $1.50M | $2.33M |
| Goodwill | $5.83M | $5.83M | — | — | — |
| Intangibles | $4.27M | $5.50M | $0 | — | — |
| Total assets | $107.61M | $122.37M | $155.29M | $111.64M | $54.33M |
| Current liabilities | $44.99M | $51.51M | $22.21M | $18.77M | $17.31M |
| Short-term debt | $6.25M | $6.25M | $6.25M | $6.25M | $5.00M |
| Long-term debt | $95.78M | $101.20M | $106.63M | $112.09M | $31.96M |
| Total debt | $102.03M | $107.45M | $112.88M | $118.34M | $36.96M |
| Total liabilities | $158.01M | $224.57M | $191.84M | $169.92M | $50.20M |
| Shareholders' equity | -$58.54M | -$105.93M | -$29.40M | -$44.46M | $4.12M |
| Net debt | $77.91M | $68.11M | $23.88M | $39.10M | $10.20M |
| Shares outstanding | — | — | — | 58.22M | — |
| Cash flow statement | |||||
| Operating cash flow | $35.19M | $45.24M | $26.88M | -$9.16M | $33.72M |
| Capital expenditure | $5.01M | $6.43M | $359,000 | $333,000 | $1.45M |
| Free cash flow | $30.18M | $38.81M | $26.52M | -$9.49M | $32.27M |
| Investing cash flow | -$6.86M | -$18.80M | -$2.71M | -$1.84M | -$3.81M |
| Financing cash flow | -$43.55M | -$76.08M | -$14.38M | $63.46M | -$20.34M |
| Depreciation & amortization | $3.67M | $3.57M | $2.99M | $2.20M | $1.40M |
| Stock-based compensation | $8.92M | $8.73M | $9.06M | $82.18M | — |
| Dividends paid | $1.73M | $4.74M | $8.69M | $12.89M | $11.40M |
| Share buybacks | $3.37M | $5.60M | — | — | — |
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.